The first subject enrolled in the FORWARD research on Furmonertinib-based adjuvant treatment

June 30 marked another milestone in the FORWARD research on Furmonertinib-based adjuvant treatment — the first subject enrolled in Jinlin Guowen Hospital. This marks not only the start of the subject enrollment process by clinical research centers across China for the FORWARD research, but also a solid step forward in the exploration of Furmonertinib-based treatment solutions for patients with EGFR mutation-positive NSCLC at the early or metaphase stage.

Introduction to the research:

FORWARD research is a 3-phase registered clinical study launched by Allist and led by He Jianxing, President of the First Affiliated Hospital of Guangzhou Medical University, one that is randomized, double-blind, placebo-controlled, and multi-centered. It will include patients with EGFR mutation-positive NSCLC of II-IIIA stage who have received radical excision with or without aid chemotherapy, and compare the efficacy and safety of Furmonertinib-based aid therapy and those of placebo-based aid therapy over a period of 3 years. The research is planning to recruit 318 subjects from around 55 sites across China.

As of July 1, 2021, FORWARD research has been launched by over 10 research centers across the country (see the list below), with more joining in the coming days.

Research CenterPI
The First Affiliate Hospital of GUANGZHOU Medical UniversityHe Jianxing
Jinzhou Central HospitalWang Wei
Harbin Medical University Cancer HospitalXu Shidong
Jilin Guowen HospitalYu Xinhang
Shanghai Chest HospitalYao Feng
Affiliated Taihe Hospital of Hubei University of MedicineLuo Zhiguo
Hubei Cancer HospitalXiong Fei
Huai’an First People’s HospitalMeng Zili
Gansu Provincial HospitalGou Yunjiu
Sir Run Run Shaw Hospital, Zhejiang University School of MedicineYing Kejing

About Furmonertinib

Furmonertinib targets adult patients who used to experience progression of disease amid or after treatments with epidermal growth factor receptor (EGFR) — tyrosine kinase inhibitor (TKI) and diagnosed with EGFR T790M mutation-positive, locally advanced or metastatic NSCLC. Boasting bi-functionality, high selectivity, strong effect in tumor regression, and high security, Furmonertinib is the third generation of EGFR-TKI that China self-developed with independent intellectual property rights.

About Allist

Founded in March 2004, Shanghai Allist Pharmaceuticals Co., Ltd. is an innovative drug developer, producer and seller dedicated to the field of lung cancer treatment oriented toward the demands in the global pharmaceutical market. With the philosophy of innovation for life, Allist has set the paramount target of developing first-in-class and best-in-class medicines. After 16 years of unremitting efforts, Allist now boasts strong comprehensive competitiveness in developing and producing on a continuous basis effective and optimal anti-cancer new drugs with independent intellectual property rights.

On December 2, 2020, Shanghai Allist Pharmaceuticals Co., Ltd. went public on the STAR market via the Shanghai Stock Exchange (Stock code: 688578).